- Home
- DYAI vs VNRX Comparison
DYAI vs VNRX Comparison
Compare DYAI & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- VNRX
- Stock Information
- Founded
- DYAI 1979
- VNRX N/A
- Country
- DYAI United States
- VNRX United States
- Employees
- DYAI N/A
- VNRX N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DYAI Health Care
- VNRX Health Care
- Exchange
- DYAI Nasdaq
- VNRX Nasdaq
- Market Cap
- DYAI 35.5M
- VNRX 45.2M
- IPO Year
- DYAI 2004
- VNRX N/A
- Fundamental
- Price
- DYAI $1.07
- VNRX $0.50
- Analyst Decision
- DYAI Strong Buy
- VNRX Strong Buy
- Analyst Count
- DYAI 1
- VNRX 5
- Target Price
- DYAI $6.00
- VNRX $3.75
- AVG Volume (30 Days)
- DYAI 35.9K
- VNRX 167.9K
- Earning Date
- DYAI 05-14-2025
- VNRX 05-20-2025
- Dividend Yield
- DYAI N/A
- VNRX N/A
- EPS Growth
- DYAI N/A
- VNRX N/A
- EPS
- DYAI N/A
- VNRX N/A
- Revenue
- DYAI $3,495,389.00
- VNRX $1,233,511.00
- Revenue This Year
- DYAI $117.40
- VNRX $563.72
- Revenue Next Year
- DYAI N/A
- VNRX $160.43
- P/E Ratio
- DYAI N/A
- VNRX N/A
- Revenue Growth
- DYAI 20.58
- VNRX 59.10
- 52 Week Low
- DYAI $0.93
- VNRX $0.42
- 52 Week High
- DYAI $2.67
- VNRX $0.90
- Technical
- Relative Strength Index (RSI)
- DYAI 28.15
- VNRX 47.94
- Support Level
- DYAI $1.05
- VNRX $0.46
- Resistance Level
- DYAI $1.21
- VNRX $0.54
- Average True Range (ATR)
- DYAI 0.07
- VNRX 0.04
- MACD
- DYAI -0.01
- VNRX 0.01
- Stochastic Oscillator
- DYAI 8.33
- VNRX 48.00
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.